← All Crispr Therapeutics AG filings

Crispr Therapeutics AG DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CRSP
Crispr Therapeutics AG
DEF: CRISPR Therapeutics AG Schedules 2026 Annual General Meeting
CRISPR Therapeutics AG has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 4, 2026, to vote on key corporate matters including financial statements, director elections, and compensation.
NASDAQ
CRSP
Crispr Therapeutics AG
DEFA14A: CRISPR Therapeutics Sets Date for 2025 Annual General Meeting, Outlines Key Proposals
CRISPR Therapeutics has scheduled its 2025 Annual General Meeting for June 5, 2025, and is seeking shareholder votes on key proposals including the approval of financial statements, director elections, and executive compensation.
NASDAQ
CRSP
Crispr Therapeutics AG
DEF: CRISPR Therapeutics Sets Date for 2025 Annual General Meeting, Proposes Board Member Re-elections and Compensation Approvals
CRISPR Therapeutics announces its 2025 Annual General Meeting to be held on June 5, 2025, featuring proposals for board member re-elections, executive compensation approvals, and an increase in the maximum size of the Board of Directors.
NASDAQ
CRSP
Crispr Therapeutics AG
DEFA14A: CRISPR Therapeutics AG Announces 2024 Annual General Meeting Agenda
CRISPR Therapeutics AG's upcoming Annual General Meeting on May 30, 2024, will address key proposals including financial approvals, board and committee elections, executive compensation, and amendments to equity plans and capital structure.
NASDAQ
CRSP
Crispr Therapeutics AG
DEF 14A: CRISPR Therapeutics Sets Date for 2024 Annual General Meeting, Outlines Key Proposals
CRISPR Therapeutics announces its 2024 Annual General Meeting to be held on May 30, 2024, featuring proposals ranging from financial approvals to board member elections and compensation matters.